Novel oral targeted therapies in inflammatory bowel disease
Background: There is a great unmet clinical need for efficacious, tolerable, economical and orally administrated drugs for the treatment of inflammatory bowel disease (IBD). New therapeutic avenues have become possible including the development of medications that target specific genetic pathways fo...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Wiley
2018
|
| Subjects: | |
| Online Access: | https://eprints.nottingham.ac.uk/50666/ |
| _version_ | 1848798309396774912 |
|---|---|
| author | White, Jonathan Richard Philips, Frank Monaghan, Tanya M. Fateen, Waleed Samuel, Sunil Ghosh, Subrata Moran, Gordon W. |
| author_facet | White, Jonathan Richard Philips, Frank Monaghan, Tanya M. Fateen, Waleed Samuel, Sunil Ghosh, Subrata Moran, Gordon W. |
| author_sort | White, Jonathan Richard |
| building | Nottingham Research Data Repository |
| collection | Online Access |
| description | Background: There is a great unmet clinical need for efficacious, tolerable, economical and orally administrated drugs for the treatment of inflammatory bowel disease (IBD). New therapeutic avenues have become possible including the development of medications that target specific genetic pathways found to be relevant in other immune mediated diseases.
Aims: To provide an overview of recent clinical trials for new generation oral targeted medications that may have a future role in IBD management.
Methods: Pubmed and Medline searches were performed up to 01/03/18 using keywords: ‘IBD’, ‘UC’, ‘CD’, ‘inflammatory bowel disease’ ‘ulcerative colitis’, Crohn’s disease’ in combination with ‘phase’, ‘study’, ‘trial’, and ‘oral’. A manual search of the clinical trial register, article reference lists, abstracts from meetings of Digestive Disease Week, United European Gastroenterology Week and ECCO congress were also conducted.
Results: In randomised controlled trials primary efficacy endpoints were met for tofacitinib (JAK 1/3 inhibitor-phase III), upadacitinib (JAK 1 inhibitor-phase II) and AJM-300 (α4-integrin antagonist-phase II) in ulcerative colitis. Ozanimod (S1P receptor agonist-phase II) also demonstrated clinical remission. For Crohn’s disease, filgotinib (JAK1 inhibitor-phase II) met primary endpoints and laquinimod (quinolone-3-carboxide small molecule-phase II) was also efficacious. Trials using mongersen (SMAD7 inhibitor) and vidofludimus (dihydroorotate dehydrogenase inhibitor) have been halted.
Conclusions: This is potentially the start of an exciting new era in which multiple therapeutic options are at the disposal of physicians to treat IBD on an individualised basis. Head-to-head studies with existing treatments and longer term safety data are needed for this to be possible. |
| first_indexed | 2025-11-14T20:17:43Z |
| format | Article |
| id | nottingham-50666 |
| institution | University of Nottingham Malaysia Campus |
| institution_category | Local University |
| last_indexed | 2025-11-14T20:17:43Z |
| publishDate | 2018 |
| publisher | Wiley |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | nottingham-506662020-05-04T19:44:19Z https://eprints.nottingham.ac.uk/50666/ Novel oral targeted therapies in inflammatory bowel disease White, Jonathan Richard Philips, Frank Monaghan, Tanya M. Fateen, Waleed Samuel, Sunil Ghosh, Subrata Moran, Gordon W. Background: There is a great unmet clinical need for efficacious, tolerable, economical and orally administrated drugs for the treatment of inflammatory bowel disease (IBD). New therapeutic avenues have become possible including the development of medications that target specific genetic pathways found to be relevant in other immune mediated diseases. Aims: To provide an overview of recent clinical trials for new generation oral targeted medications that may have a future role in IBD management. Methods: Pubmed and Medline searches were performed up to 01/03/18 using keywords: ‘IBD’, ‘UC’, ‘CD’, ‘inflammatory bowel disease’ ‘ulcerative colitis’, Crohn’s disease’ in combination with ‘phase’, ‘study’, ‘trial’, and ‘oral’. A manual search of the clinical trial register, article reference lists, abstracts from meetings of Digestive Disease Week, United European Gastroenterology Week and ECCO congress were also conducted. Results: In randomised controlled trials primary efficacy endpoints were met for tofacitinib (JAK 1/3 inhibitor-phase III), upadacitinib (JAK 1 inhibitor-phase II) and AJM-300 (α4-integrin antagonist-phase II) in ulcerative colitis. Ozanimod (S1P receptor agonist-phase II) also demonstrated clinical remission. For Crohn’s disease, filgotinib (JAK1 inhibitor-phase II) met primary endpoints and laquinimod (quinolone-3-carboxide small molecule-phase II) was also efficacious. Trials using mongersen (SMAD7 inhibitor) and vidofludimus (dihydroorotate dehydrogenase inhibitor) have been halted. Conclusions: This is potentially the start of an exciting new era in which multiple therapeutic options are at the disposal of physicians to treat IBD on an individualised basis. Head-to-head studies with existing treatments and longer term safety data are needed for this to be possible. Wiley 2018-06-30 Article PeerReviewed White, Jonathan Richard, Philips, Frank, Monaghan, Tanya M., Fateen, Waleed, Samuel, Sunil, Ghosh, Subrata and Moran, Gordon W. (2018) Novel oral targeted therapies in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 47 (12). pp. 1610-1622. ISSN 1365-2036 Inflammatory bowel disease Crohn’s disease ulcerative colitis immunotherapy https://onlinelibrary.wiley.com/doi/abs/10.1111/apt.14669 doi:10.1111/apt.14669 doi:10.1111/apt.14669 |
| spellingShingle | Inflammatory bowel disease Crohn’s disease ulcerative colitis immunotherapy White, Jonathan Richard Philips, Frank Monaghan, Tanya M. Fateen, Waleed Samuel, Sunil Ghosh, Subrata Moran, Gordon W. Novel oral targeted therapies in inflammatory bowel disease |
| title | Novel oral targeted therapies in inflammatory bowel disease |
| title_full | Novel oral targeted therapies in inflammatory bowel disease |
| title_fullStr | Novel oral targeted therapies in inflammatory bowel disease |
| title_full_unstemmed | Novel oral targeted therapies in inflammatory bowel disease |
| title_short | Novel oral targeted therapies in inflammatory bowel disease |
| title_sort | novel oral targeted therapies in inflammatory bowel disease |
| topic | Inflammatory bowel disease Crohn’s disease ulcerative colitis immunotherapy |
| url | https://eprints.nottingham.ac.uk/50666/ https://eprints.nottingham.ac.uk/50666/ https://eprints.nottingham.ac.uk/50666/ |